摘要
目的探讨卡培他滨节拍化疗联合依西美坦对绝经后孕激素受体(PR)阳性乳腺癌患者生存期的影响。方法选择2014年7月-2017年7月我院收治的92例绝经后PR阳性乳腺癌患者为研究对象,采用随机数字表法分为观察组和对照组,各46例。观察组患者给予卡培他滨节拍化疗+依西美坦治疗,对照组患者给予卡培他滨常规化疗+依西美坦治疗。比较两组患者疗效、不良反应、生活质量以及生存时间。结果两组患者治疗有效率(RR)和疾病控制率(DCR)比较,差异均无统计学意义(P>0.05);观察组患者骨髓抑制、消化道反应、手足综合征等不良反应发生率均显著低于对照组(P<0.05),生活质量改善情况显著优于对照组(P<0.05);两组患者中位肿瘤无进展生存时间(PFS)比较,差异无统计学意义(P>0.05)。结论与常规剂量治疗方案比较,卡培他滨节拍化疗联合依西美坦治疗绝经后PR阳性乳腺癌的疗效和生存期相当,但节拍化疗可减少不良反应,更有利于提高患者的生活质量。
Objective To explore the effects of capecitabine metronomic chemotherapy combined with exemestane on the survival time of patients with postmenopausal progesterone receptor(PR)-positive breast cancer.Methods A total of 92 patients with postmenopausal PR-positive breast cancer in our hospital were selected for the study and were divided into observation group and control group according to the random number table method,with 46 cases in each group.Observation group was given capecitabine metronomic chemotherapy plus exemestane,and control group was given conventional capecitabine chemotherapy plus exemestane.The efficacy,adverse reactions,quality of life improvement and the survival time were compared between the two groups.Results There were no significant differences in RR and DCR between the two groups(P>0.05).The incidence rates of adverse reactions like bone marrow suppression,digestive tract reaction and hand-foot syndrome in observation group were lower than in control group(P<0.05),and the quality of life improvement was better in observation group than in control group(P<0.05).There was no significant difference in the median tumor progression-free survival time(PFS)between the two groups(P>0.05).Conclusions Capecitabine metronomic chemotherapy combined with exemestane for postmenopausal PR-positive breast cancer achieved equal efficacy and survival time to conventional treatment regimen.However,metronomic chemotherapy can reduce the adverse reactions and help to improve the quality of life.
作者
王江涛
王鹏
刘烨
沈华
WANG Jiangtao;WANG Peng;LIU Ye;SHEN Hua(Department of Breast Diseases,Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing,Jiangsu,210000,China;Department of Gynecology,Chinese People’s Liberation Army General Hospital,Beijing,100853,China)
出处
《肿瘤药学》
CAS
2019年第1期82-85,共4页
Anti-Tumor Pharmacy
基金
江苏省自然科学基金(BK20151356)
关键词
卡培他滨
节拍化疗
依西美坦
乳腺癌
生存期
Capecitabine
Metronomic chemotherapy
Exemestane
Breast cancer
Survival time
